Kymera Therapeutics, Inc. KYMR

KYMR Company Overview

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule therapies that selectively degrade disease-causing proteins. The company operates within the biotechnology and pharmaceutical research and development industries, with a primary emphasis on immune-inflammatory and immuno-oncology diseases. Kymera’s core scientific approach is based on targeted protein degradation, particularly through heterobifunctional molecules designed to harness the body’s natural protein disposal systems.

The company’s primary value proposition lies in its proprietary protein degrader platform, which enables the modulation of previously undruggable targets. Kymera generates value primarily through internal drug development programs and strategic collaborations with large pharmaceutical partners. Founded in 2016, Kymera evolved from early academic research into protein degradation and has since advanced multiple programs into clinical development, establishing itself as a pioneer in this emerging therapeutic modality.